The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
Use at an assay dependent concentration. Inhibition of ConA/PMA induced proliferation: 10µg/ml.Mitogenic sudies: 1 µg/ml.
Use at an assay dependent concentration. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
The CD3 complex mediates signal transduction.
Involvement in disease
Defects in CD3D are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)/B(+)/NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Immunohistochemistry (Frozen sections) analysis of lymph node tissue from Rhesus macaque labeling CD3 with ab25109 at 1/100 dilution. Tissue was fixed in acetone, blocked using 10% goat serum/PBS for 15 min at 21°C, then incubated with Anti-CD3 antibody [FN-18] (ab25109) at 1/100 dilution for 16 hours at 4°C. An undiluted HRP-conjugated goat anti-mouse polyclonal was used as the secondary antibody.
References for Anti-CD3 antibody [FN-18] (ab25109)
This product has been referenced in:
Stebbings R et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol179:3325-31 (2007).
Read more (PubMed: 17709549) »